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Summary
RalGEFs were recently shown to be critical for Ras-mediated transformed and tumorigenic growth of human cells. We
now show that the oncogenic activity of these proteins is propagated by activation of one RalGEF substrate, RalA, but
blunted by another closely related substrate, RalB, and that the oncogenic signaling requires binding of the RalBP1 and
exocyst subunit effector proteins. Knockdown of RalA expression impeded, if not abolished, the ability of human cancer
cells to form tumors. RalA was also commonly activated in a panel of cell lines from pancreatic cancers, a disease
characterized by activation of Ras. Activation of RalA signaling thus appears to be a critical step in Ras-induced trans-
formation and tumorigenesis of human cells.S I G N I F I C A N C E
Ras is activated in one-third of human cancers, making it important to elucidate the oncogenic signals emanating from this protein
in order to develop anticancer agents to treat Ras-mediated cancers. While much effort has focused on the MAPK pathway as the
key pathway downstream of Ras, based on murine studies, recent evidence points toward another class of Ras effectors, the
RalGEFs, as also playing a critical role in human cell transformation and tumorigenesis. We now report that a substrate of RalGEFs,
RalA, is critical for Ras-mediated tumor growth of human cancer cells and is commonly activated in human pancreatic cancer cell
lines. As such, this protein represents a novel target for therapeutic intervention.Introduction
The genes encoding the small GTPase Ras are mutated to
yield proteins that remain in the constitutively active GTP
bound state in one-third of all human cancers, where they act
as oncoproteins and promote cancer-like growth of mamma-
lian cells (Bos, 1989). At least three primary Ras binding pro-
teins, or effectors, propagate oncogenic Ras signals: the Raf
family of serine/threonine kinases that activate the ERK mito-
gen-activated protein kinase (MAPK) pathway, known to pro-
mote cell proliferation; the phosphatidylinositol 3-kinases
(PI3Ks), known to promote cell survival; and the Ral guanine
nucleotide exchange factors (RalGEFs), activators of the RalA
and RalB Ras-related small GTPases (Shields et al., 2000).
Activation of Raf or its downstream targets promotes soft
agar growth of rodent fibroblast, a transformed phenotype of
cancer cells, and tumor formation (Shields et al., 2000). On the
other hand, neither RalGEFs nor PI3Ks are particularly trans-
forming. Activated RalGEF or Ral proteins do not cause potent
transformed growth of rodent fibroblast or epithelial cells (Col-
lette et al., 2004; McFall et al., 2001; Ulku and Der, 2003; UranoCANCER CELL : JUNE 2005 · VOL. 7 · COPYRIGHT © 2005 ELSEVIER INC.et al., 1996), although they do enhance transformation of NIH
3T3 cells expressing an activated version of Raf (Urano et al.,
1996) or rat fibroblasts expressing the EGF receptor (Lu et al.,
2000), and dominant-negative Ral mutants suppressed Ras-
induced transformation of NIH 3T3 cells (White et al., 1996).
Similarly, activated PI3K alone is not transforming, but en-
hances the transforming activity of Raf and, when inhibited,
blocks Ras-mediated transformed cell growth of NIH 3T3 cells
(Rodriguez-Viciana et al., 1997).
Unlike the situation in mice, however, the RalGEF pathway
appears to play a more prominent role in transformation of hu-
man cells. Specifically, normal human cells from a wide
spectrum of cell types are driven to a tumorigenic state upon
the expression of four proteins: SV40 T-Ag, which inhibits the
function of the tumor suppressors p53 and the Rb pocket pro-
teins; SV40 t-Ag, which indirectly activates c-Myc; the hTERT
catalytic subunit of telomerase, which is essential for the can-
cer phenotype of unlimited growth; and oncogenic (G12V) Ras
(Hahn et al., 1999; O’Hayer and Counter, 2005). Using this ap-
proach to transform identically matched primary human and
mice cells, it was found that murine cells were most potentlyDOI 10.1016/j.ccr.2005.04.030 533
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mutants that preferentially activate only one of the major effec-
tor pathways or with activated versions of the effectors them-
selves, whereas human cell transformation was mediated by
activation of the RalGEF family of proteins. Moreover, the tu-
mor growth of the human cells was dependant upon the Ras
effector mutant that activates RalGEFs. Impeding RalGEF
function via the expression of a dominant-negative version of
its substrate also diminished Ras-mediated transformation of
the same human cells (Hamad et al., 2002; Rangarajan et al.,
2004). Given the importance of RalGEF activation for trans-
formation of human cells, understanding how the RalGEF on-
cogenic signal is transmitted could provide insight into the
mechanism of Ras-induced human tumorigenesis.
Four human RalGEFs that share a common C-terminal Ras
association domain have been identified. GTP bound Ras relo-
cates RalGEFs to the membrane fraction where they can pro-
mote the exchange of GDP to GTP on their only known sub-
strates, the membrane bound GTP binding proteins RalA and
RalB (Kishida et al., 1997; Matsubara et al., 1999). The catalytic
activity of RalGEFs is also stimulated upon the association with
the protein kinase PDK1 (Tian et al., 2002), and RalGEFs have
been reported to have functions independent of the exchange
activity (Bhattacharya et al., 2002; Tian et al., 2002). In regard
to transformation, overexpression of activated Ral fosters an-
chorage-independent growth and cell motility in a number of
human cancer cell lines (Gildea et al., 2002; Ward et al., 2001;
Yamazaki et al., 2001). Additionally, disruption of Ral activation
with either small interfering RNAs (siRNA) or inhibition of Ral
effector activation impairs the growth of several human cancer
cell lines in short-term suspension culture (Chien and White, 2003).
To date, three classes of Ral effectors have been identified:
the Cdc42/Rac GTPase-activating protein RalBP/RLIP76; the
Sec5 and Exo84 subunits of the exocyst complex; and the ac-
tin binding protein filamin (Cantor et al., 1995; Jullien-Flores et
al., 1995; Moskalenko et al., 2002; Moskalenko et al., 2003;
Ohta et al., 1999; Park and Weinberg, 1995). Both RalA and
RalB also bind constitutively to phospholipase D1 (PLD1) (Luo
et al., 1997) and stimulate the activation of c-src, c-jun, AFX,
STAT, and NF-κB, as well as cyclin D, through as yet uniden-
tified effectors (de Ruiter et al., 2000; Goi et al., 2000; Henry et
al., 2000; Kops et al., 1999). To add to the complexity, despite
greater than 85% identity, RalA and RalB appear to perform
different functions. For instance, RalA has a much higher affin-
ity for the exocyst complex than does RalB, and only RalA
stimulates exocyst function to enhance the rate of delivery of
membrane proteins to the basolateral membrane of epithelial
cells (Shipitsin and Feig, 2004). It has also been reported that
suppression of RalA by siRNA inhibits cancer cell growth in
suspension culture, whereas similar suppression of RalB in
these cells leads to apoptosis (Chien and White, 2003). As Ral-
GEFs are important for Ras-induced tumorigenesis of human
cells and accumulating data suggest that Ral proteins may me-
diate functions of RalGEFs, we explored whether the RalGEF
substrates RalA and RalB play a role in transformed and tumor-
igenic growth of human cells.
Results and discussion
The GTP exchange activity of a RalGEF is necessary
for human cell transformation
Since there is evidence for Ral-independent functions of Ral-
GEFs (Bhattacharya et al., 2002; Tian et al., 2002), as a first534step to delineate the signaling pathways through which RalGEF
transforms human cells, we tested whether the GTP exchange
activity of the RalGEF Rlf was required for transformation. A
retrovirus encoding no transgene as a control, or wild-type or
catalytically dead R328E mutant version of Rlf fused to the
plasma membrane targeting domain of K-Ras (termed CAAX),
which is used to mimic the recruitment of Rlf to the plasma
membrane during Ras stimulation (de Ruiter et al., 2000; Wol-
thuis et al., 1996; Wolthuis et al., 1997), were used to infect
HEK-HT cells, primary human embryonic kidney cells that ec-
topically express hTERT, T-Ag and t-Ag (Hahn et al., 1999).
These cells provide a genetically defined human cell system to
assay Ras oncogenesis (Hamad et al., 2002). Expression of the
desired proteins in the resultant polyclonal populations was
confirmed by immunoblot analysis (Figure 1A). We also verified
that these two forms of Rlf-CAAX did not activate the Raf/MEK/
ERK and PI3K/Akt pathways, by measuring the level of phos-
phorylated forms of ERK1/2 and Akt via immunoblot analysis
in serum-starved cells. As a control, we confirmed that Akt and
ERK1/2 are highly phosphorylated upon expression of RasG12V
(Figure 1A). The cells were next assayed for anchorage-inde-
pendent growth when suspended in soft agar, one of the most
stringent in vitro measures of the transformed phenotypes typi-
cal of cancer cells. Consistent with previous results (Hamad et
al., 2002), expression of Rlf-CAAX alone was transforming, to
approximately half the level of anchorage-independent growth
observed in HEK-HT cells expressing the 37G effector domain
mutant of oncogenic Ras (not shown) that is partially defective
at activating PI3K and MAPK, but retains the ability to activate
RalGEFs (Rodriguez-Viciana et al., 1996; Shields et al., 2000;
White et al., 1995; White et al., 1996). However, the catalytically
dead RlfR328E-CAAX failed to transform human cells (Figure
1B), indicating that Ral GTPase activation is likely responsible
for RalGEF-mediated transformation.
Activation of RalA, but not of RalB,
transforms human cells
We next determined which of the RalA or RalB proteins was
responsible for RalGEF-mediated transformation by assaying
whether activated forms of RalA or RalB alone could transform
human cells. We used RalA and RalB mutated to G23V or Q72L
to disrupt their intrinsic and GTPase activating protein (GAP)-
stimulated GTPase activity, which leaves the proteins in a con-
stitutively active GTP bound state and insensitive to Ral-GAP
activity (Emkey et al., 1991; Frech et al., 1990), or RalA and
RalB mutated to F39L, which is analogous to the same muta-
tion in Ras that promotes fast cycling between GDP and GTP
bound states (Reinstein et al., 1991), as such a mutation mim-
ics interaction with GEFs and is oncogenic in both Ras and
Rho small GTPases (Lin et al., 1997; Reinstein et al., 1991).
These three mutants and their wild-type counterparts were sta-
bly expressed in HEK-HT cells, as assessed by immunoblot
analysis. As expected, these proteins did not activate the PI3K
or MAPK pathways (Figure 1A). When the resulting cells were
assayed for growth in soft agar, no version of RalB supported
anchorage-independent growth, consistent with our previous
results that RalB was not transforming (Hamad et al., 2002).
Conversely, all RalA proteins transformed HEK-HT cells to
some degree, although the most transforming versions were
clearly those with the activating (G23V or Q72L) mutations (Fig-
ure 1B). The number and size of colonies observed in cellsCANCER CELL : JUNE 2005
A R T I C L EFigure 1. Activated RalA promotes anchorage-
independent growth in human kidney and fibro-
blast cells
Immunoblot analysis of HA-epitope-tagged Rlf-
CAAX, Ras, RalA, and RalB in HEK-HT cells (A) or
BJ-HT (C) cells stably infected with retroviruses
encoding the described transgenes. MAPK and
PI3K activity were measured in the described
cells by detecting phosphorylation of ERK1/2
(P-ERK1/2) and Akt (P-Akt), respectively, with
phosphospecific antibodies. Actin, total ERK1/2,
and total Akt served as loading controls. An-
chorage-independent growth of HEK-HT (B) and
BJ-HT cells (D) expressing the described
transgenes, as calculated from the average
number of colonies ±SD from six plates (two in-
dependent experiments conducted in tripli-
cate) and expressed as the percentage of col-
onies in Rlf-CAAX-transformed cells. *, p =
0.00002 between vector and RalA; **, p = 0.002
between RalA and RalAF39L (two-tailed Stu-
dent’s t test)expressing activated RalA were smaller than those observed
in the positive control, Rlf-CAAX-expressing cells. As such, all
cultures were assayed for anchorage-independent growth 1
week later than typically needed to detect soft agar growth.
Since Rlf-CAAX was more transforming than activated RalA, it
is possible that either RalGEF signaling involves more than the
mere activation of RalA, or that expression of constitutively ac-
tivated RalA mutants fails to recapitulate either the magnitude
or proper localization of RalA activated by RalGEFs that is
needed to promote full transformation. Nevertheless, as acti-
vated forms of RalA, and no variant of RalB, transformed hu-
man cells, the signaling events leading to anchorage-indepen-
dent growth in the RalGEF pathway involve activation of RalA.
We next confirmed the transforming activity of RalA in a
completely different cell type. Normal human fibroblasts ectop-
ically expressing hTERT, T-Ag, and t-Ag (BJ-HT cells; Hahn et
al., 1999) were stably infected with retroviruses encoding wild-
type or the Q72L-activated versions of RalA or RalB, or Rlf-
CAAX (as a positive control), or the catalytically dead version
of Rlf-CAAX or no transgene (as negative controls). Resultant
polyclonal populations were confirmed to express the desired
protein by immunoblot analysis (Figure 1C) and assayed for
anchorage-independent growth. Although Ras-mediated trans-
formation of human fibroblasts can be weaker than that ob-
served in HEK cells (Hahn et al., 1999; Hamad et al., 2002),CANCER CELL : JUNE 2005constitutively activated RalA (RalAQ72L) and, to a very small de-
gree, wild-type RalA, but not any version of RalB, was also
transforming in fibroblasts (Figure 1D). Given the fact that acti-
vated RalA alone caused growth transformation of two very
different human cell types, we argue that activation of this pro-
tein may be broadly sufficient to promote Ras-mediated trans-
formation of human cells.
Inhibition of RalA binding to RalBP1 and Sec5
suppresses transformation
RalA is known to bind to and promote the activation of a num-
ber of proteins, including phospholipase D1 (PLD1), the Sec5
and Exo84 subunits of the exocyst complex, and the Cdc42/
Rac GTPase-activating protein RalBP1/RLIP76 (Cantor et al.,
1995; Jullien-Flores et al., 1995; Moskalenko et al., 2002; Ohta
et al., 1999; Park and Weinberg, 1995). PLD1 binding is medi-
ated through the N terminus of RalA, whereas binding to the
other proteins is mediated through the core effector loop region
within the conserved switch 1 domain. Ral also contains the
conserved switch 2 region that, together with the switch 1 re-
gion, changes the conformation during GDP/GTP cycling, as
well as a C-terminal hypervariable domain that appears to de-
termine the proper subcellular localization of the protein with a
highly conserved CAAX tetrapeptide motif, which signals for
the posttranslational modification by geranylgeranyl isoprenoid535
A R T I C L Elipid essential for membrane association and biological activity
(Figure 2A). To address which effectors of RalA are required for
transformation, we examined the transforming ability of a panel
of activated RalA mutants selectively defective in interacting
with the aforementioned binding proteins. Specifically, the
N11RalAQ72L mutant is truncated in the first 11 amino acid,
reducing PLD1 binding (Jiang et al., 1995); the RalAD49E,Q72L
mutant is defective in binding to Sec5 and Exo84 (Moskalenko
et al., 2002; Moskalenko et al., 2003); and the RalAD49N,Q72L
mutant has diminished affinity for RalBP1 (Cantor et al., 1995).
These different RalAQ72L mutants were stably expressed, as
assessed by immunoblot analysis, in HEK-HT cells (Figure 2B)
and assayed for growth in soft agar. The N11RalAQ72L re-
tained the transforming potency of RalAQ72L, indicating that
binding between RalA and PLD1 is not essential for RalA-medi-
ated cellular transformation (Figure 2C). In agreement, we find
that activated RalA is the most transforming (Figures 1B, 1D,
and 2C), even though PLD1 can also bind to RalA in the GDP
bound inactive state (Jiang et al., 1995). Mutations disrupting
RalA binding to RalBP1 or Sec5, however, reduced anchorage-
independent growth by up to ~70%, supporting the idea thatFigure 2. RalA-mediated transformation is de-
pendent on the effector binding and C-terminal
localization domains
A: Schematic representation of RalAQ72L effec-
tor mutants. PLD, PLD binding domain; SW1and
SW2, switch domains 1 and 2; Var, C-terminal
hypervariable domain.
B: Detection of RalA protein by immunoblot
analysis in HEK-HT cells stably infected with a ret-
roviral vector encoding no transgene (vector)
or one of the described RalAQ72L mutants. Actin
serves as a loading control.
C: Anchorage-independent growth of poly-
clonal HEK-HT cells stably expressing the indi-
cated RalAQ72L effector mutants, as calculated
from the average number of colonies ± SD from
six plates (two independent experiments con-
ducted in triplicate) and expressed as the per-
centage of colonies detected in RalAQ72L-
transformed cells.536binding to these two proteins may be important for full RalA-
mediated transformation.
RalB inhibits RalGEF-mediated transformation
Activated RalB alone was not transforming, despite being
>85% identical to RalA and capable of binding RalA effectors.
To further explore the relationship between RalA and RalB in
transformation, we tested whether ectopic expression of wild-
type RalB could inhibit RalGEF-induced transformation. Wild-
type RalA, RalB, or a vector control was stably expressed in
HEK-HT cells harboring either Rlf-CAAX, to activate the Ral
proteins, or, as a negative control, the catalytically dead
RlfR328E-CAAX protein (Figure 3A). Wild-type RalA, which was
extremely weak in transforming in the presence of RlfR328E-
CAAX, slightly enhanced the transforming ability of Rlf-CAAX
(Figure 3B), whereas a constitutively active RalA was even
more potent (Figures 3C and 3D). Conversely, wild-type RalB
reduced the transforming ability of Rlf-CAAX by 40%–50%.
On the basis of these observations, we reasoned that ec-
topic RalB may compete with endogenous RalA for Rlf-CAAX,
as well as for RalA effectors needed for transformation. In sup-CANCER CELL : JUNE 2005
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transformation
A, C, and E: Detection of HA-epitope-tagged
Rlf-CAAX, RalA, and RalB by immunoblot analy-
sis in HEK-HT cells stably infected with retroviruses
encoding the described transgenes. Actin
serves as a loading control.
B, D, and F: Anchorage-independent growth of
polyclonal HEK-HT cells stably expressing the in-
dicated combinations of transgenes calculated
from the average number of colonies ± SD from
six plates (two independent experiments con-
ducted in triplicate), expressed as the percen-
tage of colonies observed in Rlf-CAAX- trans-
formed cells.port of this model, expression of RalB mutants defective in
binding to either Sec5 and Exo84 (D49E) or RalBP1 (D49N)
inhibited Rlf-CAAX-mediated transformation as well as RalB,
suggesting that the mode inhibition involves competition for
Rlf-CAAX. However, upon making RalB independent of RalGEF
activation via the Q72L mutation, RalBQ72L could clearly inhibit
Rlf-CAAX-mediated transformation, and this inhibition was re-
duced 40% to 50% upon disrupting binding to the exocyst
complex (RalBQ72L,D49E); in contrast, disruption of RalBP1
binding (RalBQ72L,D49N) did not affect the activity of RalBQ72L in
inhibiting Rlf-CAAX-mediated transformation, in agreement
with RalB competing for RalA effectors (Figures 3E and 3F). It is
worth noting that the inhibition depended upon overexpressing
RalB, as ectopic RalB impeded transformation mediated by
endogenous RalA, but not in cells overexpressing RalAQ72L
(Figures 3C and 3D). Thus, whereas RalA mediates RalGEF-
induced transformation, this transformation can be blunted by
overexpression of RalB, possibly by competition for RalGEF
activation and RalA effectors.CANCER CELL : JUNE 2005Subcellular localization contributes to the ability of RalA
and RalB to affect transformation
Our previous study using the MDCK cell line showed not only
that active RalA binds more effectively to the exocyst than
does RalB, but also that active RalA, but not RalB, localizes to
perinuclear recycling endosomes (Shipitsin and Feig, 2004). In
HEK-HT cells, endogenous RalA and RalB were mostly punctu-
ate throughout the cytoplasm and generally did not colocalize,
as assessed by immunofluorescence analysis. Upon stimula-
tion of endogenous Ral proteins by ectopic RasG12V, there was
a relatively greater increase in the concentrations of RalA com-
pared to RalB in vesicular-like bodies in the perinuclear region
(Figure 4A). We thus postulated that these differences in the
subcellular localization of RalA and RalB may contribute to
their ability to function in a pro- or antioncogenic fashion.
The C terminus of RalA possesses a hypervariable region
terminating in a CAAX motif, both of which are known to be
essential for proper localization of active RalA and for its func-
tion as a stimulator of secretion (Shipitsin and Feig, 2004). To537
A R T I C L EFigure 4. Subcellular localization underlies the
ability of RalA and RalB to promote or inhibit
transformation, respectively
A: Detection of endogenous RalA and RalB by
immunofluorescence analysis in HEK-HT cells sta-
bly expressing the empty vector control or
RasG12V (upper 2 rows) or myc epitope-tagged
RalBQ72L/A and endogenous RalA or flag epi-
tope-tagged RalAQ72L/B and endogenous RalB
(lower 2 rows) in HEK-HT cells stably expressing
myc-RalBQ72L/A or flag-RalAQ72L/B, respectively.
B: Schematic representation of RalQ72L chimeras
in which the C terminus of RalA (gray) or RalB
(white) is replaced with the C terminus of the
opposite Ral protein.
C: Detection of RalA, RalB, or the chimeric ver-
sions by immunoblot analysis in the described
HEK-HT cells with antibodies that recognize the
N-terminal regions of the proteins. Actin serves
as a loading control.
D: Anchorage-independent growth of poly-
clonal HEK-HT cells stably expressing the indi-
cated Ral proteins, as calculated from the
average number of colonies ± SD from six plates
(two independent experiments conducted in
triplicate), expressed as the percentage of col-
onies observed in RalAQ72L-transformed cells.determine whether these domains are essential for RalA-medi-
ated transformation, we removed the C-terminal hypervariable
region (RalAQ72L,Var) or the CAAX motif (RalAQ72L,CAAX; Figure
2A) from RalAQ72L and expressed these two mutants in HEK-
HT cells (Figure 2B). When assayed in soft agar, we found that
disrupting either of these C-terminal regions reduced the trans-
forming capability of RalAQ72L almost to the level of negative
control vector cells (Figure 2C). Thus, proper subcellular local-
ization is required for Ral-mediated transformation.
Because activated RalA and RalB reside in different sets of
membrane compartments and as this localization is mediated
by C-terminal regions of the proteins that are required for RalA
transformation, we surmised that RalB could be converted, at
least partially, to a transforming protein by targeting it to the
subcellular domains occupied by activated RalA. We therefore
expressed in human HEK-HT cells an activated RalB (RalBQ72L)
in which the C-terminal domain was replaced with the corre-
sponding region from RalA (Figures 4B and 4C). As previously
described in MDCK cells (Shipitsin and Feig, 2004), the
RalBQ72L/A protein associated with perinuclear vesicle-like
bodies, which is not normally seen with wild-type RalB, even
in RasG12V overexpressing cells (Figure 4A, second row). Colo-
calization of RalBQ72L/A with endogenous RalA in these vesi-
cles was also substantially increased (Figure 4A, third row).
This altered localization endowed RalB with the ability to trans-
form human cells. HEK-HT cells expressing RalBQ72L/A were
able to grow in soft agar, albeit at ~50% of the transformation538efficiency of RalAQ72L (Figure 4D). Thus, targeting RalB, a pro-
tein that normally inhibits transformation, to sites of activated
RalA endowed RalB with transforming functions.
The opposite was also true—namely, targeting RalA to RalB
subcellular domains impeded the transforming activity of RalA.
When the C-terminal hypervariable region of RalA was
switched to that of RalB (Figure 4B) and expressed in HEK-
HT cells (Figure 4C), the resultant RalAQ72L/B chimera failed to
colocalize with RalA-associated vesicles. Instead, there was an
overall increase of colocalization of RalAQ72L/B with endoge-
nous RalB throughout the cytoplasm (Figure 4A, fourth row).
Consistent with this mislocalization, the RalAQ72L/B mutant
showed a 40% to 50% decrease in its ability to support an-
chorage-independent growth compared to RalAQ72L.
We surmise that the distinct subcellular localization of acti-
vated RalA and RalB may play a role in the effect of these
proteins on cell transformation. However, the transforming ac-
tivity of RalA was not completely abolished by mislocalizing,
nor was RalB as efficient at transformation as RalA when
targeted to RalA-associated vesicles (Figure 4D). These find-
ings are consistent with our previous observation that RalA and
RalB also differ in their ability to bind to at least one effector,
the exocyst complex, with RalA binding more strongly to the
exocyst than RalB (Shipitsin and Feig, 2004). Thus, in addition
to the distinct subcellular localization patterns of RalA and
RalB, differential affinities for effectors may also contribute to
the disparate transforming potential of these two proteins.CANCER CELL : JUNE 2005
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Ectopically expressed RalA is transforming, whereas RalB im-
pedes transformation. Given the inherent limitations of inter-
preting phenotypes resulting from overexpressed proteins, we
confirmed these results by loss-of-function analysis. Endoge-
nous RalA, RalB, or both, were stably knocked down by siRNAs
directed against the mRNAs encoding these proteins in HEK-
HT cells expressing RasG12V, RasG12V,E37G, or Rlf-CAAX (Figure
5A). For negative controls, an empty vector or one encoding
scrambled versions of the siRNA sequences were introduced
into the transformed HEK-HT cells. All 12 cell lines were then
assayed for growth in soft agar. Consistent with RalA activation
being critical for Ras-mediated transformation, knockdown of
RalA in HEK-HT cells transformed via activation of the RalGEF
pathway, by either RasG12V,E37G or Rlf-CAAX, nearly abolished
transformation and reduced oncogenic Ras-transformed cell
growth by more than half (Figure 5B). This was not an off-target
effect of RNAi, as identical results were obtained with indepen-
dent siRNA generated against different regions of RalA and
RalB (see Figure S1 in the Supplemental Data available withFigure 5. RalA is critical for Ras-induced trans-
formation
A: Detection of RalA, RalB, and Ras by immu-
noblot analysis in HEK-HT cells transformed by
RasG12V, RasG12V,E37G, Rlf-CAAX, or RalAQ72L and
subsequently stably infected with retroviral vec-
tors encoding siRNA (+) targeting RalA, RalB, or
both, or as negative control, a scramble se-
quence (S). Actin level serves as a loading
control.
B: Anchorage-independent growth of poly-
clonal HEK-HT cells transformed by the de-
scribed transgenes stably expressing the indi-
cated siRNA against RalA and/or RalB, or a
scramble sequence (scram) as negative con-
trol, as calculated from the average number of
colonies ± SD from six plates (two independent
experiments conducted in triplicate), expressed
as the percentage of colonies observed in
scramble control- treated cells.CANCER CELL : JUNE 2005this article online). Perhaps related, transient knockdown of
RalA was shown to decrease the proliferation of human cancer
cells when suspended in media (Chien and White, 2003).
Conversely, knockdown of RalB in HEK-HT cells transformed
via activation of the RalGEF pathway led to an increase in
growth in soft agar. This effect was even greater in cells trans-
formed by oncogenic RalA, indicating that the antioncogenic
activity of RalB is mediated, at least in part, through antagoniz-
ing the transforming activity of RalA (Figure 5B). However, in
the more oncogenic situation in RasG12V- transformed cells,
knockdown of RalB had no measurable effect. Although tran-
sient knockdown of RalB was previously reported to greatly
reduce the proliferative potential of cancer cells by stimulating
apoptosis (Chien and White, 2003), this does not appear to be
the case with stable expression of the described RalB siRNA
in HEK-HT cells or in four human pancreatic cancer cell lines
(Figures 5B and 7B). This discrepancy is due to a difference in
cell type, the degree of inhibition of RalB expression, or the
method by which RNAi is performed. In fact, the increase in
transformation upon stable knockdown of RalB that we de-539
A R T I C L Etected is in complete agreement with the observation that
overexpression of RalB inhibited transformation by Rlf-CAAX
(Figures 3B and 3D). Lastly, we noted that simultaneous knock-
down of both RalA and RalB was somewhat more potent than
was knockdown of RalA alone in inhibiting the transforming
ability of RasG12V,E37G or Rlf-CAAX, perhaps reflecting a general
requirement for some level of Ral signaling. In summary, the
described loss-of-function studies support the conclusions
drawn from analysis of cells overexpressing RalA or RalB: i.e.,
activated RalA and RalB primarily oppose one another in trans-
formation, with RalA mediating, and RalB inhibiting RalGEF on-
cogenic signaling.
RalA is critical for Ras-induced tumorigenesis
Given the importance of RalA in Ras-mediated transformation,
we next addressed the role of each Ral protein in the most
stringent assay: tumorigenesis. RalA and/or RalB were stably
knocked down by siRNA in the highly tumorigenic RasG12V-
transformed HEK-HT cells (Figures 5A and 6C), and the resul-
tant cells were injected into immunocompromised mice. As a
control, we utilized the same cells engineered to express the
corresponding scrambled counterparts. Consistent with the
soft agar results, reducing RalB expression had only marginal
effects on RasG12V-mediated tumor growth, perhaps because
loss of RalB can do little to enhance the already extremely tu-
morigenic functions of Ras (Figure 6A). Also consistent with the
in vitro experiments, loss of RalA in RasG12V-transformed HEK-
HT caused a 2-fold increase in the latency period and a reduc-
tion in the growth kinetics of the outgrowing tumors (Figure
6A). In cases in which tumors eventually did arise, RalA expres-
sion was restored, possibly through in vivo selection of cells
from the initial polyclonal population that had low levels of
siRNA (Figure 6C). Knockdown of RalA had no measurable ef-
fect on the ability of the cells to survive and proliferate in vitro;Figure 6. RalA is critical for Ras-induced tumori-
genesis
A: Tumor volume (mm3) ± SD versus time (days)
of HEK-HT-RasG12V cells stably expressing a Ral
scramble sequence ($), RalA-siRNA(■), RalB-
siRNA (C), RalA and RalB siRNA (:) or RalA-
siRNA in the presence of siRNA-resistant wild-type
RalA (%) injected into a flank of immunocom-
promised mice.
B: Cell number ± SD versus time (days) of cul-
tured HEK-HT-RasG12V cells stably expressing a
scramble sequence (,), RalA-siRNA (■), RalB-
siRNA (C), or RalA and RalB-siRNA (:).
C: Detection of RalA by immunoblot analysis in
HEK-HT-RasG12V cells infected with retroviruses
encoding a scramble sequence (scram) or
RalA-siRNA before implantation (preimplant)
into immunocompromised mice, or in cells puri-
fied from three resultant tumors (1, 2, 3). Actin
serves as a loading control.
D: Detection of RalA by immunoblot analysis in
RalA knockdown HEK-HT-RasG12V cells stably ex-
pressing a Ral scramble sequence (scram), RalA
siRNA alone (RalA siRNA), or in the presence of
an siRNA-resistant wild-type RalA (RalA rescue).
Actin serves as a loading control.540thus, any effect observed must be related to tumorigenesis
(Figure 6B). Lastly, the loss of tumorigenic potential by RalA
knockdown was completely reversed by expression of a RalA
protein engineered to be resistant to RalA siRNA (Figures 6A
and 6D). Thus, activation of RalA is critical, if not essential, for
Ras-mediated tumorigenic growth of human HEK-HT cells.
Suppression of RalA inhibits the tumorigenic growth
of human cancer cell lines
We next addressed whether RalA expression was required for
tumorigenic growth of human cancer cell lines harboring an
activated Ras mutation. To this end, a retrovirus expressing
either the RalA siRNA or the scrambled sequence was stably
introduced into the human cancer cell line HT1080, a fibrosar-
coma cell line, J82, a bladder cell carcinoma cell line, and
SW620, a colon adenocarcinoma cell line (Brown et al., 1984;
Di Paolo et al., 2001; Fujita et al., 1988), and the resultant cells
were shown to have either reduced or unaltered levels of RalA,
respectively (Figure 7A). Scramble control cells in all three
cases readily formed tumors when injected into immunocom-
promised mice, whereas suppression of RalA increased the lat-
ency period of tumor initiation and decreased the tumor growth
kinetics. These decreases were slight in the case of SW620
cells, whereas knockdown of RalA in the J82 cell line abolished
the tumorigenic potential of these cells as no tumors were de-
tected even after 100 days, fully 5-fold longer than the average
time taken to initiate tumor growth in the presence of RalA (Fig-
ure 7B). Thus, RalA is important, and possibly essential in
some cases, for the tumorigenic growth of human cancer cell
lines with an activated Ras pathway.
RalA is in the GTP bound active state in pancreatic
cancer cell lines
To further explore the role of RalA in human cancer, we asked
to what extent RalA exists in the GTP bound, active state inCANCER CELL : JUNE 2005
A R T I C L EFigure 7. A critical role of RalA in tumorigenic
growth of human cancer cell lines
A: Detection of RalA by immunoblot analysis in
the described cancer cell lines stably infected
with retroviral vectors encoding siRNA against
RalA or the scramble control (scram). Actin
serves as a loading control.
B: Average tumor volume (mm3) ± SD versus
time (days) of the indicated cancer cell lines ex-
pressing siRNA against RalA (■) or scramble
control (,) injected into immunocompromised
mice.cells of cancers characterized by oncogenic Ras mutations.
K-Ras is mutated in almost 90% of tumors from patients diag-
nosed with pancreatic cancer (Bos, 1989). Hence, we mea-
sured the levels of GTP bound and total RalA in a panel of 14
pancreatic human cancer cell lines, most of which were known
to have an activating mutation in one allele of the K-Ras gene
(Berrozpe et al., 1994; Calhoun et al., 2003; Iwamura and Hol-
lingsworth, 1998; Kalthoff et al., 1993; Moore et al., 2001; Ryu
et al., 2002). Immunoblot analysis revealed that total RalA pro-
tein was present, at variable levels, in all of these tumor cell
lines. RalA-GTP protein was isolated via an interaction with a
recombinant polypeptide encoding the Ral binding domain of
the Ral effector protein RalBP1, followed by immunoblot analy-
sis to detect RalA (Wolthuis et al., 1998a; Wolthuis et al.,
1998b). While undetectable or low levels of RalA-GTP were
seen in a subset of the cell lines (Figure 8A, CFPac-1, Colo
357, and Colo 587), similar to the levels seen in a variety of
untransformed epithelial cells (McFall et al., 2001; Ulku and
Der, 2003) and in normal human pancreatic tissue (Figure 8B),
total RalA-GTP levels were elevated in the remaining majority
of cell lines (Figure 8A). This level of RalA-GTP elevation is
comparable to that in a variety of Ras-transformed cells
(McFall et al., 2001; Ulku and Der, 2003) and was reduced upon
the knockdown of oncogenic K-Ras in Capan-1 cells (Figure
8B), arguing that this level of RalA-GTP represents an abnormal
activation of RalA. In contrast, while RalB protein was detected
in these cancer cell lines, RalB-GTP levels were only highly
elevated in three of the lines. In summary, the transforming
RalA protein, but not the nontransforming RalB protein, is pref-
erentially in its activated state in human pancreatic cancer
cells.
Most surprisingly, RalA was more commonly activated com-
pared to the other major Ras effector pathways in these cancer
cell lines. While ERK1/2 were phosphorylated to some degreeCANCER CELL : JUNE 2005in at least 11 of the lines, high levels of ERK phosphorylation
were only seen in one-third of these lines. Similarly, AKT was
only weakly activated in the panel of cancer cell lines, with high
levels of phosphorylated AKT detected in just three lines (Fig-
ure 8A). Intriguingly, we also found that the total K-Ras protein
and K-Ras-GTP levels varied enormously among the cancer
cell lines, again despite the fact that RalA-GTP was usually
readily detected, suggesting a need to conserve RalA activa-
tion, even in the event of diminished Ras protein levels (Figure
8A). In support of this model, independent of the amount of
RalA, RalB, PI3K, or MAPK activation, we showed that knock-
down of RalA in four of these human pancreatic cancer cell
lines almost uniformly reduced their ability to grow in soft agar.
Conversely, knockdown of RalB in the same cell lines had little
or no effect on the ability of the cells to grow on plastic or in
suspension (Figure 8C and data not shown). The finding of
RalA being commonly activated in pancreatic cancer cell lines
is consistent with a critical role for this effector in tumori-
genesis.
RalA and RalB function in Ras oncogenesis
We show that RalA is a principal effector of RalGEFs involved
in Ras-mediated transformation and tumorigenesis, as a con-
stitutively active version of RalA promoted anchorage-indepen-
dent growth whereas inhibition of RalA expression lowered,
and, in some cases actually abolished, Ras-mediated trans-
formation and tumorigenesis. While this pathway was not
strongly transforming on its own—indicating a collaborative
role with other Ras effector pathways—decreasing RalA ex-
pression clearly reduced tumorigenic growth. As a decrease of
RalA expression had no obvious effect on the cells until they
were placed in an oncogenic environment, aberrant RalA acti-
vation presumably performs a task required uniquely in the pro-
cess of tumorigenesis.541
A R T I C L EFigure 8. RalA is commonly activated in pancreatic cancer cells to promote transformed cell growth
A: Detection of activated GTP bound K-Ras, RalA, and RalB via association with effector protein domains specific for activated versions of these proteins,
followed by immunoblot analysis with antibodies specific for K-Ras, RalA, or RalB in a panel of 14 pancreatic cancer cell lines. Detection of MAPK and PI3K
activation in the same cell lines, by immunoblot analysis with phosphospecific antibodies for phosphorylated forms of ERK1/2 (P-ERK1/2) and Akt (P-Akt),
respectively. Total K-Ras, RalA, RalB, ERK1/2 and Akt, or actin, serve as loading controls.
B: Detection of activated GTP bound RalA via association with an effector protein domain specific for the activated version of this protein followed by
immunoblot analysis with an antibody specific for RalA in normal human pancreatic tissues from three separate donors (1, 2, and 3) or Capan-1 cells
stably infected with a control retrovirus (v) or one encoding siRNA specific to the 12V mutant allele of K-Ras that knocks down K-Ras expression, as
determined by immunoblot analysis. Total RalA or actin serve as loading controls.
C: Detection of RalA or RalB by immunoblot analysis in the described pancreatic cancer cell lines stably infected with retroviral vector alone (vector) or
encoding siRNA targeting RalA or RalB. Actin serves as a loading control. Bottom: anchorage-independent growth of the indicated cell lines, as calculated
from the average number of colonies from three plates and expressed as the percentage of colonies observed in vector control cells, except for Capan-2
cultures, which were only counted in one plate because replica plates showed no visible difference in colony formation among the three cell lines.Ral proteins have been implicated in the regulation of a vari-
ety of cellular functions that could conceivably account for their
oncogenic activity, including enhancement of gene transcrip-
tion and regulation of vesicle trafficking. We favor the latter
possibility because enhancement of transcription is mediated
by both RalA and RalB (Goi et al., 2000; Henry et al., 2000),
while in our assays only RalA promoted transformation. More-
over, RalA, but not RalB, promotes basolateral membrane de-
livery in MDCK cells (Shipitsin and Feig, 2004), as well as trans-
formed and tumorigenic growth of human cells. Both of these
activities require proper localization to perinuclear vesicles and
depend upon the C-terminal variable domain of RalA. Replac-
ing this domain with that of RalB decreased the transforming
and membrane delivery activities of RalA, while replacing the
C terminus of RalB with that of RalA endowed RalB with partial
transforming and membrane delivery activities. How the effects
of RalA on vesicle sorting may be linked to its ability to trans-
form human cells is not yet clear. Perhaps Ral-exocyst interac-
tions are involved in secretion, which could be a factor in au-
tocrine stimulation of cells, similar to the proposed role of
Cdc42 in the transformation of cells (Wu et al., 2003). Alterna-
tively, Ral-exocyst interactions are also thought to be critical542for filopodia formation (Ohta et al., 1999; Takaya et al., 2004),
which may be needed for transformation-associated remodel-
ing of cell structure.
While RalA behaved in an oncogenic fashion, RalB func-
tioned in exactly the opposite manner. RalB overexpression in-
hibited, while RalB siRNA treatment enhanced, Rlf-CAAX
transformation. We suggest that the modus operandi of RalB
antioncogenic behavior may be to both compete for binding
to RalGEFs, resulting in a decrease in RalA activation, and to
sequester Ral effectors to subcellular sites nonproductive for
oncogenic signaling, akin to the roles proposed for RalB in in-
hibiting Ral-mediated basolateral membrane delivery (Shipitsin
and Feig, 2004). However, RalB was rather ineffectual at block-
ing Ras-mediated transformation. This could be because Ras
activates pathways that circumvent RalB inhibitory signals, be-
cause RalA competes more successfully for effector binding,
or because RalA is preferentially activated in cancer cells, as
supported by the observation that RalA, and not RalB, was
commonly activated in our panel of 14 human pancreatic can-
cer cell lines. Similarly opposing functions in growth regulation
have been described for the highly related RhoA and RhoB
small GTPases (Adnane et al., 2002; Jiang et al., 2004). DespiteCANCER CELL : JUNE 2005
A R T I C L Estrong sequence identity and similar effector interaction, RhoA
activation has been associated with growth promotion, whereas
RhoB exhibits the characteristics of a tumor suppressor (Jiang
et al., 2004). The functional differences between RhoA and
RhoB have been ascribed to differences in subcellular localiza-
tion (Wang et al., 2003).
In summary, we show that RalA plays a central role in Ras-
mediated tumorigenesis, as loss of RalA function impedes, if
not abolishes, the growth of human tumor cells and is widely
activated in pancreatic cancer cell lines. Inhibiting RalA func-
tion may therefore be an effective anti-Ras strategy for can-
cer treatment.
Experimental procedures
Cell lines
Human embryonic kidney cells (HEK-HT) and BJ fibroblasts (BJ-HT) stably
expressing the early region of SV40 encoding T-Ag and t-Ag and hTERT
were previously described (Hahn et al., 1999; Hamad et al., 2002). HT1080
and J82 cell lines were obtained from ATCC; the SW620 cell line or normal
human pancreas tissues from three different donors were kind gifts of X.-F.
Wang or A.D. Proia and D. Tyler, respectively (Duke University Medical Cen-
ter, Durham, NC). HT1080 and SW620 cell lines are known to contain a
mutant Ras allele (Brown et al., 1984; Di Paolo et al., 2001; Fujita et al.,
1988). The J82 cell line was confirmed by RT-PCR and direct sequencing
to contain a G12V mutation in H-Ras. The pancreatic cell lines were ob-
tained from ATCC or are kind gifts of Dr. Bernard E. Weismann (University
of North Carolina, Chapel Hill, NC) and Dr. Murray Korc (University of Cali-
fornia, Irvine, CA). To measure proliferation rate, each cell line was seeded
at 10,000 cells per 6 cm dishes and viable (Trypan blue- negative) cells were
counted daily for 6 days. Indicated cell lines were infected with retroviruses
generated from the described retroviral vectors encoding no protein, the
indicated proteins, or siRNA, followed by appropriate exposure to puromy-
cin, zeocin, or neomycin to select for stably infected polyclonal populations
(O’Hayer and Counter, 2005).
Plasmids and cDNAs
Retroviral constructs used were pBabeBleo or pBabepuro with no insert or
cDNAs encoding H-RasG12V, H-RasG12V,E37G (Hamad et al., 2002), HA-Rlf-
CAAX (Wolthuis et al., 1997), RalA, RalB (Guthrie Research Institute), HA-
RlfR328E-CAAX, RalAG23V, RalAF39L, RalAQ72L, RalBG23V, RalBQ72L, RalBF39L,
and RalA and RalB effectors mutants (generated by site-directed mutagen-
esis or by PCR), or N-terminally flag-tagged RalAQ72L/B and Myc-tagged
RalBQ72L/A (tagged versions of cDNAs described by (Shipitsin and Feig,
2004)). RalA siRNA sequence AAGACAGGTTTCTGTAGAAGA (and as an
alternate: AACAGAGCTGAGCAGTGGAAT), RalB siRNA sequence GACTAT
GAACCTACCAAAG (and as an alternate: GGTGATCATGGTTGGCAGC),
scramble controls in which several mutations were introduced into these
sequences, or siRNA specific for K-RasG12V (Brummelkamp et al., 2002)
were cloned into pSUPER-RETRO-PURO or pSUPER-RETRO-GFP/NEO
(Oligoengine). siRNA-resistant RalA was generated by introducing silent
mutations (bold italics) AGTAAGCGTT.
Immunoblot
Lysates from the described cell lines were immunoblotted with the antibod-
ies α-Pan-Ras (Oncogene), α-HA (Roche), α-actin (Santa Cruz), α-Raf-1
(Santa Cruz), α-RalA and α-RalB (Transduction Laboratory). Akt and ERK1/2
total protein or phosphorylated forms were detected from cells cultured in
medium containing 0.5% fetal bovine serum for 48 hr by immunoblot analy-
sis with the antibodies α-Akt (Cell Signaling Technology), S472 α-phospho(Ser
473)-Akt (New England Biolabs), K-23 α-ERK1/2 (Santa Cruz), and E10
α-phospho(Thr 202/Tyr 204)-p42/44 MAPK (Cell Signaling Technology). Ral-
GTP and Ras-GTP levels were detected as previously described (de Rooij
and Bos, 1997; Wolthuis et al., 1998a), by capture with bacterially ex-
pressed GST-RalBD of RalBP1 or GST-RasBD of Raf1, followed by immu-
noblot analysis with the aforementioned RalA, RalB, or Ras antibodies.CANCER CELL : JUNE 2005Immunofluorescence
The described cells were plated on glass microslides the previous day,
fixed, permeabilized, and incubated with anti-Flag, anti-Myc (9E10), anti-
RalA, and anti-RalB primary antibodies, followed by the appropriate HRP-
conjugated secondary antibodies (Jackson Immunoresearch Laboratory) as
previously described (Etheridge et al., 2002).
Soft agar
50,000 cells per 3cm plate were suspended in soft agar as described (Ci-
fone and Fidler, 1980; Hamad et al., 2002) and colonies >30 cells scored
after 4 weeks. Assays were performed in triplicate and at least twice inde-
pendently.
Tumorigenesis
According to a protocol approved by the Duke University Institutional Ani-
mal Care and Use Committee, 1 × 107 cells mixed with Matrigel were in-
jected subcutaneously into the flanks of 4 SCID/beige mice per cell line,
after which tumor volumes were determined at regular intervals as de-
scribed previously (Hamad et al., 2002). Tumors were harvested, minced,
and trypsinized for 2 hr at 37°C and then passed through 18G needles,
washed, and plated in DMEM/10% FBS plus puromycin at least 4 days
before immunoblot analysis was performed.
Supplemental Data
Supplemental Data include one figure and can be found with this article
online at http://www.cancercell.org/cgi/content/full/7/6/533/DC1/.
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